Carregant...
Reimbursement recommendations for cancer drugs supported by phase II evidence in Canada
BACKGROUND: Phase ii data are increasingly being used as primary evidence for public reimbursement for oncologic drugs. We compared the frequency of reimbursement recommendations for phase ii and phase iii submissions and assessed for variables associated with a positive or conditional recommendatio...
Guardat en:
| Publicat a: | Curr Oncol |
|---|---|
| Autors principals: | , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Multimed Inc.
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7606040/ https://ncbi.nlm.nih.gov/pubmed/33173389 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3747/co.27.6489 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|